RegenMatrix PRP-HA

RegenMatrix PRP-HA is a medical device and combination product developed by RegenLab France SAS for the treatment of moderate to severe knee osteoarthritis (Kellgren-Lawrence grade III-IV). It is an adaptation of the Cellular Matrix technology, designed to prepare a combination of autologous platelet-rich plasma (PRP) and cross-linked hyaluronic acid (HA) in a single closed system for intra-articular injection. The mechanism of action is dual: the PRP component provides a concentrated source of autologous growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF), which stimulate chondrocyte proliferation, reduce inflammation, and promote tissue repair. Simultaneously, the cross-linked hyaluronic acid provides immediate viscosupplementation, restoring the rheological properties of the synovial fluid and providing mechanical pain relief and cushioning within the joint.

Brand names

RegenMatrix

Other names

RegenMatrix PRP-XLHA